Enrique Diloné

Enrique Diloné is Chief Technology Officer at Prothelia. Prior to Prothelia, Dr. Diloné served as Senior Vice President, Technical Operations at Amicus Therapeutics. During his 10 year tenure at Amicus Therapeutics, Enrique led the Technical Operations group through the CMC development and commercialization of Galafold®, as well as the development of Amicus’ pipeline including human recombinant GAA enzyme (ATB200), oral small molecules, sterile injectables and AAV based gene therapies. Prior to joining Amicus, Enrique served as Executive Director of Quality and Analytics at NovaDel Pharma Inc. from 2007 to 2009. He served as Director/Senior Director of Analytical Operations at OSI/Eyetech Pharmaceuticals from 2002 to 2006. Enrique also worked in several pharmaceutical development departments at Wyeth and Hoffmann-La Roche. Enrique has over 25 years experience in the pharmaceutical and biotechnology industries and has contributed to the approval of several other commercial products (ZolpiMist®, MACUGEN®, ZENAPAX®) and to the development and manufacture of several more clinical products. Enrique received a B.A. in Chemistry from New York University, and a M.S. and a Ph.D., in Chemistry, from Seton Hall University. Enrique is a graduate of the General Management Program at Harvard Business School, and is certified in U.S. Regulatory Affairs.